535
Participants
Start Date
June 30, 2014
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
Chiglitazar
Take orally
Placebo
Take orally
Peking University Shougang Hospital, Beijing
China Meitan General Hospital, Beijing
Peking University People's Hospital, Beijing
The 306th Hospital of PLA, Beijing
The Second Hospital of Jilin University, Changchun
The First Affiliated Hospital of Ha'erbin Medical University, Harbin
Zhongshan Hospital Fudan University, Shanghai
Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
The Central Hospital of Yangpu District of Shanghai, Shanghai
The people's Hospital of Jiangsu Province, Nanjing
The Affiliated Hospital of Xuzhou Medical College, Xuzhou
The Affiliated Hospital of Qingdao Medical University, Qingdao
The General Hospital of Tianjin Medical University, Tianjin
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Chongqing Three Gorges Central Hospital, Chongqing
The Second Xiangya Hospital of Central South University, Changsha
Chenzhou First People's Hospital, Chenzhou
Zhongnan Hospital of Wuhan University, Wuhan
Huaxi Hopsital of Sichuan University, Chengdu
The First Affiliated Hospital of The 4th Military Medical University, Xi’an
Cangzhou's Central Hospital, Cangzhou
Harrison International Peace Hospital, Hengshui
The Third Hospital of Hebei Medical University, Shijiazhuang
Tangshan Gongren Hospital, Tangshan
Baogang Hospital of Inner Mongilia, Baotou
Lead Sponsor
Chipscreen Biosciences, Ltd.
INDUSTRY